CTenaLouise
03-07-2009, 09:27 PM
Teva's Azilect Use Dramatically Increases In Second-Line Therapy For The Treatment Of Parkinson's Disease
05 Mar 2009
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share was driven by growth in the use of Teva's Azilect which is attributed to physicians' growing comfort with the drug and data attesting to its possible neuroprotective (disease-modifying) effects.
http://www.medicalnewstoday.com/articles/141150.php?nfid=52345
05 Mar 2009
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share was driven by growth in the use of Teva's Azilect which is attributed to physicians' growing comfort with the drug and data attesting to its possible neuroprotective (disease-modifying) effects.
http://www.medicalnewstoday.com/articles/141150.php?nfid=52345